TapewireFind a company

person · Reporting owner

Chudnovsky Yekaterina

Disclosed activity across 3 companies

Tapewire entity
318
SEC CIK
0001979324

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Elicio Therapeutics, Inc.ELTX · Entity 299Director · 10% ownerAugust 31, 2026September 02, 2026
Immix Biopharma, Inc.IMMX · Entity 4958DirectorMay 22, 2026May 29, 2026
Xilio Therapeutics, Inc.XLO · Entity 712210% ownerJune 07, 2024September 28, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Elicio Therapeutics, Inc.

Report date August 31, 2026 · Filed September 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31Direct21,750 Reported balance After 2026-08-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750

F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Immix Biopharma, Inc.

Report date May 22, 2026 · Filed May 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,250 Reported balance After 2026-05-22 transaction · row 1
1 source row

Row 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 6,250

F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22Direct12,500 Reported balance After 2026-05-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500

F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Common StockSEC Table I · non-derivativeIndirectHeld by GKCC, LLC3,241,076 Reported balance Holding disclosure · report date 2026-05-22 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 3,241,076

F2: The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

F2: The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Xilio Therapeutics, Inc.

Report date June 07, 2024 · Filed September 28, 2024

Jointly reported with GKCC, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectHeld by GKCC, LLC7,000,000 Reported balance Holding disclosure · report date 2024-06-07 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 7,000,000

F1: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 31, 2026 Filed Sep 2, 2026 20:04 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 GrantStock Option (Right to Buy) · Derivative 21,750 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001979324-26-000002 · wk-form4_1788379464.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,750

Underlying: Common Stock · 21,750 shares

Expires 2036-08-31

F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Read SEC document
May 22, 2026 Filed May 29, 2026 21:05 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $8.78 $0.00
Disclosure

SEC source: 0001493152-26-026424 · ownership.xml · derivative · entry 3

Chudnovsky Yekaterina · CIK 0001979324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-05-22

F3 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Read SEC document
May 22, 2026 Filed May 29, 2026 21:05 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantCommon Stock 6,250 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-026424 · ownership.xml · nonDerivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:57 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantStock Option (Right to Buy) · Derivative 33,000 $0.00 Strike: $2.24 $0.00
Disclosure

SEC source: 0001641172-25-016111 · ownership.xml · derivative · entry 2

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2035-06-20

F2 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.

Read SEC document
June 03, 2025 Filed Jun 4, 2025 21:08 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 GrantWarrant (right to buy) · Derivative 103,225 $0.00 Strike: $7.75 $0.00
Disclosure

SEC source: 0000950170-25-081741 · ownership.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 103,225

Underlying: Common Stock · 103,225 shares

Expires 2030-06-03

F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Read SEC document
May 19, 2025 Filed May 20, 2025 20:05 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 GrantStock Option (Right to Buy) · Derivative 7,900 $0.00 Strike: $5.84 $0.00
Disclosure

SEC source: 0001601485-25-000084 · wk-form4_1747771529.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,900

Underlying: Common Stock · 7,900 shares

Expires 2035-05-19

F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:06 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 ConversionConvertible Note (convertible into Common Stock) · Derivative 3,442,341 $5.81 Strike: $5.81 $20,000,001.21
Disclosure

SEC source: 0000950170-25-035494 · ownership.xml · derivative · entry 2

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 0

Underlying: Common Stock · 3,442,341 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share.

F2 · derivative.expiration_date: The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share.

F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:06 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 ConversionCommon Stock 3,500,573 $5.81 $20,338,329.13
Disclosure

SEC source: 0000950170-25-035494 · ownership.xml · nonDerivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 5,416,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Read SEC document
November 21, 2024 Filed Nov 25, 2024 12:33 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 GrantStock Option (Right to Buy) · Derivative 4,100 $0.00 Strike: $5.12 $0.00
Disclosure

SEC source: 0001601485-24-000091 · wk-form4_1732537993.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,100

Underlying: Common Stock · 4,100 shares

Expires 2034-11-21

F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:41 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 PurchaseConvertible Note (convertible into Common Stock) · Derivative 3,442,341 $5.81 Strike: $5.81 $20,000,001.21
Disclosure

SEC source: 0001140361-24-037346 · form4.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 3,442,341

Underlying: Common Stock · 3,442,341 shares

Expires not disclosed

F1 · shares: On August 12, 2024, GKCC, LLC (the "Purchaser") purchased from the Issuer a convertible note with an aggregate principal amount of $20,000,000 (the "Convertible Note"). The Convertible Note is convertible into shares of common stock of the Issuer at a conversion price of $5.81 per share, subject to adjustment in certain circumstances. Therefore, the Convertible Note is initially convertible into approximately 3,442,341 shares of common stock of the Issuer.

F2 · derivative.exercise_date: The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum.

F2 · derivative.expiration_date: The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum.

F3 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of the Purchaser and may be deemed to beneficially own the shares held by the Purchaser.

Read SEC document
June 28, 2024 Filed Jul 2, 2024 20:30 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 PurchasePre-Funded Warrants · Derivative 1,600,000 $4.99 Strike: $0.01 $7,984,000.00
Disclosure

SEC source: 0001140361-24-032163 · form4.xml · derivative · entry 2

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%.

F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date.

Read SEC document
June 28, 2024 Filed Jul 2, 2024 20:30 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 PurchaseCommon Warrants · Derivative 1,600,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001140361-24-032163 · form4.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,600,000

Underlying: Common Stock · 1,600,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%.

F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029.

Read SEC document
June 11, 2024 Filed Jun 21, 2024 21:45 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantStock Option (Right to Buy) · Derivative 33,000 $0.00 Strike: $2.04 $0.00
Disclosure

SEC source: 0001493152-24-024823 · ownership.xml · derivative · entry 2

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2034-06-11

F2 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.

Read SEC document
March 19, 2024 Filed Mar 20, 2024 20:28 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 PurchasePre-Funded Common Stock Purchase Warrant · Derivative 1,032,702 $5.81 Strike: $0.01 $5,999,998.62
Disclosure

SEC source: 0000950170-24-034198 · ownership.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 1,032,702

Underlying: Common Stock · 1,032,702 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by GKCC, LLC at any time on or after March 19, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%, unless stockholder approval is obtained.

F2 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date.

F3 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Read SEC document
December 28, 2023 Filed Dec 29, 2023 22:05 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 GrantStock Option (right to buy) · Derivative 4,100 $0.00 Strike: $8.26 $0.00
Disclosure

SEC source: 0001140361-23-060238 · form4.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,100

Underlying: Common Stock · 4,100 shares

Expires 2033-12-28

F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Read SEC document
December 22, 2023 Filed Dec 26, 2023 21:29 UTC Elicio Therapeutics, Inc. ELTX · Entity 299 PurchaseCommon Stock 1,213,000 $5.81 $7,047,530.00
Disclosure

SEC source: 0001209191-23-059683 · doc4.xml · nonDerivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

GKCC, LLC · CIK 0001977769 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by GKCC, LLC

Disclosed balance after: 1,915,639

F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 20:28 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantStock Option (Right to Buy) · Derivative 16,670 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001209191-23-047062 · doc4.xml · derivative · entry 2

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,670

Underlying: Common Stock · 16,670 shares

Expires 2033-08-22

F2 · derivative.exercise_date: The Stock Option will vest in ten (10) equal monthly installments following the date of grant and any remaining unvested shares will become fully vested and exercisable on the date of the 2024 annual shareholder meeting, subject to the Reporting Person's continued service on the Board of Directors.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 20:28 UTC Immix Biopharma, Inc. IMMX · Entity 4958 GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001209191-23-047062 · doc4.xml · derivative · entry 1

Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-08-22

F1 · derivative.exercise_date: The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.